Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections. Alpha- Antitrypsin Deficiency – Therapeutics DevelopmentPipeline Overview Number of Products under Development for Alpha- Antitrypsin Deficiency, H1 2019
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)
Purchase this report at: https://www.themarketreports.com/report/buy-now/1470880
Reasons To Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Adverum Biotechnologies Inc
- Alnylam Pharmaceuticals Inc
- Applied Genetic Technologies Corp
- Arrowhead Pharmaceuticals Inc
- AstraZeneca Plc
- Editas Medicine Inc
- Grifols SA
- Inhibrx LP
- Intellia Therapeutics Inc
- International Stem Cell Corp
- Kamada Ltd
- Logicbio Therapeutics Inc
- OncBioMune Pharmaceuticals, Inc.
- PlantForm Corp
- Promethera Biosciences SA
- ProMetic Life Sciences Inc
- Santhera Pharmaceuticals Holding AG
- Vertex Pharmaceuticals Inc
- Z Factor Ltd
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1470880